Calla Lily Clinical Care
Calla Lily Clinical Care develops patented medical device technologies engineered to improve intravaginal drug delivery for women's health, focusing on clinical needs such as fertility support, pregnancy management, prevention of recurrent miscarriage, and restoration of the vaginal microbiome. Recognized for innovation, the company maintains collaborative partnerships with clinical and academic institutions and secures funding to advance clinical trials and R&D. Their technology is designed for leak prevention, convenience, and dosing confidence, with a strong commitment to sustainability and social impact as a certified B-Corporation.
Calla Lily Clinical Care
Charles House 108-110 Finchley Road London NW3 5JJ UK
Calla Lily Clinical Care is currently seeking investment
Calla Lily Clinical Care is seeking a seed investment in the range of 1m-5m
What We Do
A patented and FDA-cleared platform for intravaginal delivery of medicines and hormones, utilizing a biocompatible scaffold, mini-liner, and flexible sheath to prevent leakage, enable precise dosage, and facilitate mess-free insertion and removal.
Device under development for effective, non-invasive collection of biological samples to support biomarker-based diagnostic tests for gynecological conditions.
Collaboration with academic, NHS, and pharmaceutical partners to design and execute clinical trials evaluating drug delivery devices and platforms in reproductive health.
Development of funding strategies, grant writing, and management of relationships with funding agencies for medical device innovations.
Digital Health Technologies
Routes of Administration
FDA Regulated Medical Devices
Infectious Diseases
Application Area
Key People
Co-founder & Chairman
Co-founder & CEO
Principal Scientist
Product Development Manager
R&D Manager
Chief Product Officer
News & Updates
Secured NIHR funding for first clinical trial of the drug delivery technology in miscarriage prevention.
Certified as a B-Corp for meeting high social and environmental standards.
Obtained US FDA clearance and secured multiple patents across jurisdictions for platform technology.
Recertified to ISO9001 and began the process towards ISO13485 certification for quality management.
Recognized as one of the best startups at MedFemTech Congress in Paris.
Recognition of the Global Access Fellowship Program partnership, providing drug development experience to PharmD students for advancing healthcare access.